A common genetic defect of ovarian mucinous tumors is represented by KRAS mutations, observed in 46–55% of mucinous cystadenomas, in 63% to 73% of borderline tumors and in 75–85% of mucinous carcinomas. Here, KRAS is linked to mucinous adenocarcinoma.